Probiotics against<i>Campylobacter</i>Pathogens

Sorokulova, Irene B.; Kirik, D. L.; Pinchuk, I V

doi:10.1111/j.1708-8305.1997.tb00813.x

Cited by 30 publications

(22 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These probiotics are available as pharmaceutical and food preparations in different European countries, Japan, Russia, Ukraine, and other countries (6,14,23,26), even though little is understood about how these bacteria exert their prophylactic and therapeutic benefits.…”

Section: Discussionmentioning

confidence: 99%

“…This strain was selected as a potential probiotic because of its safety profile in humans (20) and its antagonistic properties against different pathogenic bacteria, including Campylobacter spp. (26). Members of the Bacillus genus are known to be producers of various biologically active substances (13,18,22).…”

Section: Discussionmentioning

confidence: 99%

“…The beneficial effects of certain Bacillus species (B. subtilis, Bacillus licheniformis, and Bacillus toyoi) on the balance of the gastrointestinal microflora of humans and animals are the basis of the rationale for their use as probiotics in the treatment and prevention of intestinal disorders (14,26). These probiotics are available as pharmaceutical and food preparations in different European countries, Japan, Russia, Ukraine, and other countries (6,14,23,26), even though little is understood about how these bacteria exert their prophylactic and therapeutic benefits.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, the most well-studied probiotics are the lactic acid bacteria, particularly lactobacilli, and to a lesser extent, bifidobacteria. Other organisms used or considered for use as probiotics in humans or animals include various Bacillus spp., Bacteroides spp., Propionibacterium spp., and fungi (2,23,26). Characterization and study of the mechanisms of action of these microorganisms as probiotics lag significantly behind characterization and study of those of the lactic acid bacteria.…”

mentioning

confidence: 99%

See 3 more Smart Citations

In Vitro Anti- Helicobacter pylori Activity of the Probiotic Strain Bacillus subtilis 3 Is Due to Secretion of Antibiotics

Pinchuk

Bressollier²,

Verneuil³

et al. 2001

Antimicrob Agents Chemother

205

131

View full text Add to dashboard Cite

A limited number of antibiotics can be used against Helicobacter pylori infection, and resistance jeopardizes the success of treatment. Therefore, a search for new agents is warranted. The use of probiotics to enhance gastrointestinal health has been proposed for many years, but the scientific basis of the prophylactic and therapeutic actions of probiotics has not yet been clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have antagonistic properties against species of the family Enterobacteriaceae. In the present study, it was also found to inhibit H. pylori. The anti-H. pylori activity present in the cell-free supernatant was not related to pH or organic acid concentration. It was heat stable and protease insensitive. At least two antibiotics, detected by thin-layer chromatography (R f values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic analysis, were found to be responsible for this anti-H. pylori activity. All H. pylori strains tested were sensitive to both compounds. One of these compounds was identified as amicoumacin A, an antibiotic with anti-inflammatory properties. MICs for H. pylori determined in solid and liquid media ranged between 1.7 and 6.8 g/ml and 0.75 and 2.5 g/ml, respectively. The underestimation of MICs determined in solid medium may be due to physicochemical instability of the antibiotic under these test conditions. An additive effect between amicoumacin A and the nonamicoumacin antibiotic against H. pylori was demonstrated.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

In Vitro Anti- Helicobacter pylori Activity of the Probiotic Strain Bacillus subtilis 3 Is Due to Secretion of Antibiotics

Pinchuk

Bressollier²,

Verneuil³

et al. 2001

Antimicrob Agents Chemother

205

131

View full text Add to dashboard Cite

show abstract

“…In vitro activity of B. subtilis 3 was confirmed by the results obtained in animal models. This strain showed efficacy against pathogenic cultures of Escherichia coli and Campylobacter species during treatment of experimental infections in mice and maintained normal microflora in the animals during receipt of antibiotic therapy [36,37].…”

mentioning

confidence: 99%

Preclinical Testing in the Development of Probiotics: A Regulatory Perspective withBacillusStrains as an Example

Sorokulova¹

2008

CLIN INFECT DIS

View full text Add to dashboard Cite

Preclinical testing of the microbial strains is the first important step in the development of probiotics. Requirements for the set of tests can vary depending on the bacterial species and the expected mechanism of action in the organism. Common approaches to preclinical testing of probiotic strains include strain identification (i.e., determination of phenotypic and genotypic properties), safety evaluation (i.e., characterization of history of use [safety contact], assessment of resistance to antibiotics, and evaluation of pathogenic properties in vitro and in animal models), and efficacy testing (i.e., functional characterization). Future progress in probiotics requires more studies to determine the mechanisms of their action, as well as an understanding of the basis and mechanisms of pathogenicity for different probiotic strains. Special attention should be given to recombinant probiotics, particularly in the formulation of criteria for selection of the host strain, for assessment of environmental safety, and for tracing the fate of recombinant DNA in vitro and in vivo.

show abstract

An Innovative Strategy for the Effective Reduction of MDR Pathogens from the Nosocomial Environment

Caselli

D’Accolti

Soffritti

et al. 2019

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Probiotics againstCampylobacterPathogens

Cited by 30 publications

References 3 publications

In Vitro Anti- Helicobacter pylori Activity of the Probiotic Strain Bacillus subtilis 3 Is Due to Secretion of Antibiotics

In Vitro Anti- Helicobacter pylori Activity of the Probiotic Strain Bacillus subtilis 3 Is Due to Secretion of Antibiotics

Preclinical Testing in the Development of Probiotics: A Regulatory Perspective withBacillusStrains as an Example

An Innovative Strategy for the Effective Reduction of MDR Pathogens from the Nosocomial Environment

Contact Info

Product

Resources

About